Unlocking the Potential of PDPN as a Drug Target for Alzheimer's Disease

Target Name: PDPN

NCBI ID: G10630

PDPN

Unlocking the Potential of PDPN as a Drug Target for Alzheimer's Disease

PDPN (hT1alpha-1) is a protein that is expressed in the brain and is known for its role in the development and progression of various neurological disorders, including Alzheimer's disease. The protein is composed of 21 kDa and is localized to the endoplasmic reticulum (ER) and the trans-membrane space (TMS). PDPN is a scaffold protein that plays a structural role in the organization of other proteins in the brain, and it is involved in the regulation of a variety of cellular processes, including cell adhesion, migration, and apoptosis.

PDPN is a potential drug target for the treatment of neurological disorders, including Alzheimer's disease, because of its involvement in the regulation of key cellular processes that are disrupted in these disorders. The normal function of PDPN is often disrupted in Alzheimer's disease, and the levels of the protein in the brain are typically decreased in individuals with the disease. This suggests that PDPN may be a useful biomarker for the diagnosis and progression of Alzheimer's disease.

PDPN is involved in the regulation of several cellular processes that are important for the development and progression of neurological disorders. One of the functions of PDPN is to regulate the formation of neurotransmitter-producing neurons, which are important for the function of the brain. PDPN is also involved in the regulation of the trafficking of proteins to and from the ER and TMS, which are important for the proper functioning of the brain.

In addition to its role in the regulation of neurotransmitter-producing neurons, PDPN is also involved in the regulation of the immune response. PDPN has been shown to play a role in the regulation of dendritic cell function, which is important for the development of the immune system. PDPN has also been shown to be involved in the regulation of the production of antibodies, which are important for the immune response.

PDPN is also involved in the regulation of the cell cycle. PDPN is a member of the tubulin complex, which is responsible for regulating the dynamics of microtubules in the cell. The tubulin complex plays a role in the regulation of the cell cycle, and PDPN is involved in the regulation of microtubule dynamics and the proper functioning of the cell cycle.

PDPN is also involved in the regulation of the production of neurotransmitters, such as dopamine and serotonin. PDPN has been shown to play a role in the regulation of the production of these neurotransmitters, and the levels of these neurotransmitters in the brain are typically decreased in individuals with Alzheimer's disease.

In conclusion, PDPN is a protein that is involved in the regulation of several key cellular processes that are important for the development and progression of neurological disorders. The normal function of PDPN is often disrupted in Alzheimer's disease, and the levels of the protein in the brain are typically decreased. This suggests that PDPN may be a useful biomarker for the diagnosis and progression of Alzheimer's disease, and it may also be a potential drug target for the treatment of these disorders. Further research is needed to fully understand the role of PDPN in the development and progression of Alzheimer's disease.

Protein Name: Podoplanin

Functions: Mediates effects on cell migration and adhesion through its different partners. During development plays a role in blood and lymphatic vessels separation by binding CLEC1B, triggering CLEC1B activation in platelets and leading to platelet activation and/or aggregation (PubMed:14522983, PubMed:15231832, PubMed:17616532, PubMed:18215137, PubMed:17222411). Interaction with CD9, on the contrary, attenuates platelet aggregation induced by PDPN (PubMed:18541721). Through MSN or EZR interaction promotes epithelial-mesenchymal transition (EMT) leading to ERZ phosphorylation and triggering RHOA activation leading to cell migration increase and invasiveness (PubMed:17046996, PubMed:21376833). Interaction with CD44 promotes directional cell migration in epithelial and tumor cells (PubMed:20962267). In lymph nodes (LNs), controls fibroblastic reticular cells (FRCs) adhesion to the extracellular matrix (ECM) and contraction of the actomyosin by maintaining ERM proteins (EZR; MSN and RDX) and MYL9 activation through association with unknown transmembrane proteins. Engagement of CLEC1B by PDPN promotes FRCs relaxation by blocking lateral membrane interactions leading to reduction of ERM proteins (EZR; MSN and RDX) and MYL9 activation (By similarity). Through binding with LGALS8 may participate in connection of the lymphatic endothelium to the surrounding extracellular matrix (PubMed:19268462). In keratinocytes, induces changes in cell morphology showing an elongated shape, numerous membrane protrusions, major reorganization of the actin cytoskeleton, increased motility and decreased cell adhesion (PubMed:15515019). Controls invadopodia stability and maturation leading to efficient degradation of the extracellular matrix (ECM) in tumor cells through modulation of RHOC activity in order to activate ROCK1/ROCK2 and LIMK1/LIMK2 and inactivation of CFL1 (PubMed:25486435). Required for normal lung cell proliferation and alveolus formation at birth (By similarity). Does not function as a water channel or as a regulator of aquaporin-type water channels (PubMed:9651190). Does not have any effect on folic acid or amino acid transport (By similarity)

The "PDPN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PDPN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets